Who Paid My Doc
phase III efficacy for obesity - with T2DM
Research payments
$5,742,790
Through program year 2025, $5,742,790 in research payments was reported against phase III efficacy for obesity - with T2DM, across 115 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $10,654 | 1 |
| 2024 | Research | $5,732,136 | 114 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Amit Bhalodia Camden, NJ Named on 6 payments
- Gulliermo Umpierrez Atlanta, GA Named on 4 payments
- Jose Mandry Ocoee, FL Named on 4 payments
- Donald Eagerton Myrtle Beach, SC Named on 4 payments
- Stephen Blank Atlanta, GA Named on 4 payments
- Damaris Vega Houston, TX Named on 4 payments
- Kenneth Cusi Gainesville, FL Named on 4 payments
- Suzanne Swan Minneapolis, MN Named on 4 payments
- Almena Free Anniston, AL Named on 3 payments
- Kevin Cannon Wilmington, NC Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.